GAD1 and type 1 diabetes mellitus: Recently, it was reported that the combination of GABA and GAD-alum, in a 12-month, double-blind, randomized T1D pediatric trial, significantly reduced fasting and meal-stimulated serum glucagon, but preservation of the C-peptide response was not attained, however the safety of GABA was confirmed (15).